LUREX BIO, INC filed an amended Form D with the Securities and Exchange Commission on 2026-02-05.
LUREX BIO, INC filed an amended Form D notice of an exempt securities offering with the SEC on February 5, 2026. The filing reports $150K sold. Its industry group is Biotechnology. It names George Sens (Chief Executive Officer), Mark Shumate (Vice President, Capital and Strategic Partnerships), Horace Lanier, III (Chief Operating Officer and Secretary) (SEC Form D/A, February 5, 2026).
Sell to companies like LUREX BIO, INC? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
New Form D on file · 2026-02-05 · the record
Pitching, partnering or investing alongside them? See who really runs and owns LUREX BIO, INC.
Free to see. No signup.
More on the people and the money behind LUREX BIO, INC, from the filings we hold.
Other Technology raises by companies based in Florida, filed in February 2026, largest first.
Get an email when LUREX BIO, INC files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
We'll show it in your MentionFox inbox when LUREX BIO, INC raises, hires or launches. No email unless you switch it on.
Watch LUREX BIO, INC →Get the full cited report on LUREX BIO, INC
What the filing shows about LUREX BIO, INC
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on LUREX BIO, INC: verified, sourced, every claim cited, ready in a few minutes. See pricing.
Saved here on this device in the meantime, so nothing is lost either way.
Full funding history for LUREX BIO, INC →
Amended on 2026-08-31: the amount sold changed from $50,000 to $150,000; the number of investors changed from 1 to 3. Figures on this page are from the amendment. Amended filing · Original filing
This is the company's own disclosure. A payment disclosed on a Form D is a disclosed use of proceeds, not a finding of wrongdoing.
A hollow marker is an amendment (Form D/A); a solid one is an original Form D. The larger marker is the filing this page is about.
Trailing twelve months. 759 filings in Biotechnology, totalled by week. The dot is this raise, $150K, on the same scale — one filing against the whole group's total, so it sits low by construction.
On the filing as: Executive Officer.
George Sens is named as Chief Executive Officer on the Form D that LUREX BIO, INC filed with the SEC on 5 February 2026, one of 4 people that filing names.
On the filing as: Executive Officer, Director.
Mark Shumate is named as Vice President, Capital and Strategic Partnerships on the Form D that LUREX BIO, INC filed with the SEC on 5 February 2026, one of 4 people that filing names.
On the filing as: Executive Officer, Director.
Horace Lanier, III is named as Chief Operating Officer and Secretary on the Form D that LUREX BIO, INC filed with the SEC on 5 February 2026, one of 4 people that filing names.
On the filing as: Promoter.
James Clark is named as Founder; took the initiative in founding and organizing Lurex Bio, Inc. on the Form D that LUREX BIO, INC filed with the SEC on 5 February 2026, one of 4 people that filing names.
4 people named on the filing — 3 holding an executive role and 1 named in another capacity.
Named as of the 2026-02-05 filing. Titles and locations are exactly as the filing states — not independently confirmed elsewhere.
No investor is drawn from a Form D — the form states how many invested and never who.
What the filing shows about LUREX BIO, INC
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on LUREX BIO, INC: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on LUREX BIO, INC covers
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist LUREX BIO, INCYou get an alert in MentionFox the next time this company shows up.
If you're behind LUREX BIO, INC: the weeks after a raise are watched the same way — by other investors sizing you up, and by founders checking who just got funded. FoxPlug turns your commits, deploys, and releases into that story automatically. GetFoxChat puts a guide on your own site so the people this filing just sent you don't leave after one page.
Sourced from the filing index on sec.gov.
Each opens in a new tab, filled in for LUREX BIO, INC. With no account yet, you sign up free and land on the result.
On these lists: AI and software raises in Miami
https://mentionfox.com/funding/lurex-bio-inc-form-d-26000001